Justin Mitchell Krause

Array ( [id] => 2472801 [patent_doc_number] => 04886758 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1989-12-12 [patent_title] => 'Method of determining incompatibility-reaction-causing substances in blood products as well as a method of inactivating said incompatibility-reaction-causing substances' [patent_app_type] => 1 [patent_app_number] => 6/907652 [patent_app_country] => US [patent_app_date] => 1986-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 5264 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 144 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/04/886/04886758.pdf [firstpage_image] =>[orig_patent_app_number] => 907652 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 2551781 [patent_doc_number] => 04803072 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1989-02-07 [patent_title] => 'Immunomodulation' [patent_app_type] => 1 [patent_app_number] => 6/905825 [patent_app_country] => US [patent_app_date] => 1986-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8290 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/04/803/04803072.pdf [firstpage_image] =>[orig_patent_app_number] => 905825 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 2558359 [patent_doc_number] => 04816565 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1989-03-28 [patent_title] => 'Interleukin 2 receptor and a method for production thereof' [patent_app_type] => 1 [patent_app_number] => 6/895466 [patent_app_country] => US [patent_app_date] => 1986-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 3148 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/04/816/04816565.pdf [firstpage_image] =>[orig_patent_app_number] => 895466 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 2556594 [patent_doc_number] => 04837016 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1989-06-06 [patent_title] => 'Protozoal antigen' [patent_app_type] => 1 [patent_app_number] => 6/891055 [patent_app_country] => US [patent_app_date] => 1986-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 5706 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/04/837/04837016.pdf [firstpage_image] =>[orig_patent_app_number] => 891055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 2487314 [patent_doc_number] => 04801575 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1989-01-31 [patent_title] => 'Chimeric peptides for neuropeptide delivery through the blood-brain barrier' [patent_app_type] => 1 [patent_app_number] => 6/891867 [patent_app_country] => US [patent_app_date] => 1986-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 3124 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/04/801/04801575.pdf [firstpage_image] =>[orig_patent_app_number] => 891867 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 2525272 [patent_doc_number] => 04861720 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1989-08-29 [patent_title] => 'Oncornavirus vaccines and feline alpha-type interferon' [patent_app_type] => 1 [patent_app_number] => 6/882088 [patent_app_country] => US [patent_app_date] => 1986-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8618 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/04/861/04861720.pdf [firstpage_image] =>[orig_patent_app_number] => 882088 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 2548795 [patent_doc_number] => 04814169 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1989-03-21 [patent_title] => 'Process for the production of anti-human protein antibody' [patent_app_type] => 1 [patent_app_number] => 6/878526 [patent_app_country] => US [patent_app_date] => 1986-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4784 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 175 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/04/814/04814169.pdf [firstpage_image] =>[orig_patent_app_number] => 878526 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 2519240 [patent_doc_number] => 04885166 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1989-12-05 [patent_title] => 'Hybrid interferons' [patent_app_type] => 1 [patent_app_number] => 6/871059 [patent_app_country] => US [patent_app_date] => 1986-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 24072 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 174 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/04/885/04885166.pdf [firstpage_image] =>[orig_patent_app_number] => 871059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 2593810 [patent_doc_number] => 04921697 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1990-05-01 [patent_title] => 'IFN-gamma as an active substance for inhibiting and preventing degradation processes in bone' [patent_app_type] => 1 [patent_app_number] => 6/868524 [patent_app_country] => US [patent_app_date] => 1986-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 6115 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/04/921/04921697.pdf [firstpage_image] =>[orig_patent_app_number] => 868524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 2557956 [patent_doc_number] => 04857316 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1989-08-15 [patent_title] => 'Synergistic antiviral composition' [patent_app_type] => 1 [patent_app_number] => 6/861172 [patent_app_country] => US [patent_app_date] => 1986-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5169 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/04/857/04857316.pdf [firstpage_image] =>[orig_patent_app_number] => 861172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 2604820 [patent_doc_number] => 04902506 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1990-02-20 [patent_title] => 'Immunogenic conjugates' [patent_app_type] => 1 [patent_app_number] => 6/859975 [patent_app_country] => US [patent_app_date] => 1986-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11195 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/04/902/04902506.pdf [firstpage_image] =>[orig_patent_app_number] => 859975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 2484773 [patent_doc_number] => 04801450 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1989-01-31 [patent_title] => 'High titer pseudomonas immune serum globulin' [patent_app_type] => 1 [patent_app_number] => 6/859944 [patent_app_country] => US [patent_app_date] => 1986-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3506 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/04/801/04801450.pdf [firstpage_image] =>[orig_patent_app_number] => 859944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 2512862 [patent_doc_number] => 04855134 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1989-08-08 [patent_title] => 'Sustained-release preparation' [patent_app_type] => 1 [patent_app_number] => 6/855387 [patent_app_country] => US [patent_app_date] => 1986-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 553 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/04/855/04855134.pdf [firstpage_image] =>[orig_patent_app_number] => 855387 [rel_patent_id] =>[rel_patent_doc_number] =>)